Sustained Cognitive Improvement in Alzheimer's Disease Patients Following a Precision Medicine Protocol: Case Series.
Level 4 - case-series / case-control
Uncontrolled case series
PubMed 39200239 · doi:10.3390/biomedicines12081776
What was done
Long-term follow-up (>5 years) was evaluated in patients with cognitive decline associated with Alzheimer's disease who received an individualized, multi-target precision medicine protocol (such as ReCODE).
What was found
The abstract reports sustained cognitive improvement lasting in some cases for over a decade. No quantitative scores, participant numbers, or effect sizes are reported in the abstract.
Why it matters
Standard single-agent pharmacotherapies rarely sustain multi-year cognitive improvement in Alzheimer's disease, suggesting individualized multi-target approaches warrant rigorous prospective investigation.
Limits
The study is an uncontrolled case series vulnerable to severe selection and reporting bias. The abstract provides no sample size, objective cognitive test scores, diagnostic verification, or safety data, precluding causal inference or generalizability.
Cited by
- partial A published paper demonstrates over a decade of sustained cognitive and MRI improvement in patients treated with a precision medicine approach for cognitive decline.